Ibuprofen
This article was originally published in The Tan Sheet
Executive Summary
U.S. Pharmacopeia proposes that a new limits test for 4- isobutylacetophenone be included in the ibuprofen tablets monograph. Research has shown that 4-isobutylacetophenone, a degradation product found in ibuprofen tablets made by several manufacturers, causes adverse reactions such as burning in the mouth and throat in concentrations exceeding .1%. The proposal would limit the level of 4-isobutylacetophenone to .8 mg, or.1%.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning